Clinical data | |
---|---|
Other names | K/KAN/HLK/KM[1] |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | By mouth, intravenous, intramuscular |
ATC code | |
Pharmacokinetic data | |
Bioavailability | very low after by mouth delivery |
Metabolism | Unknown |
Elimination half-life | 2 hours 30 minutes |
Excretion | Urine (as unchanged drug) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.374 |
Chemical and physical data | |
Formula | C18H36N4O11 |
Molar mass | 484.503 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Kanamycin A,[2] often referred to simply as kanamycin, is an antibiotic used to treat severe bacterial infections and tuberculosis.[3] It is not a first line treatment.[3] It is used by mouth, injection into a vein, or injection into a muscle.[3] Kanamycin is recommended for short-term use only, usually from 7 to 10 days.[3] Since antibiotics only show activity against bacteria, it is ineffective in viral infections.[3]
Common side effects include hearing and balance problems.[3] Kidney problems may also occur.[3] Kanamycin is not recommended during pregnancy as it may harm the baby.[3] It is likely safe during breastfeeding.[4] Kanamycin is in the aminoglycoside family of medications.[3] It works by blocking the production of proteins that are required for bacterial survival.[3]
Kanamycin was first isolated in 1957 by Hamao Umezawa from the bacterium Streptomyces kanamyceticus.[3][5] It was removed from the World Health Organization's List of Essential Medicines in 2019.[6][7] It is no longer marketed in the United States.[3]